On 30 May 2019 the Patented Medicine Prices Review Board (PMPRB) published the 2018 edition of the Meds Pipeline Monitor – a horizon-scanning report which provides a snapshot of the new drug landscape.(1) The PMPRB report considered the 733 medicines that are currently in Phase III clinical trials or pre-registration with the US Food and Drug Administration (FDA) and identified 30 that have the potential to:

  • address an unmet need;
  • offer an improvement over existing therapies; and
  • treat serious conditions.

These 30 medicines were also analysed for their potential budgetary impact. Of the 30 new medicines selected, 20 were designated as orphan drugs by the FDA or the European Medicines Agency (including eight gene therapies), nine were oncology medicines and three were biologics. Future editions of this annual publication will monitor the pipeline list featured in this report.

Endnotes

(1) The news release is available here.

This article was first published by the International Law Office, a premium online legal update service for major companies and law firms worldwide. Register for a free subscription.